GlaxoSmithKline to Fully Buy Cellzome AG for $99 Million

Research-based pharmaceutical and healthcare company GlaxoSmithKline PLC (GSK.LN) said Tuesday it has entered into an agreement to buy the 80.02% of Cellzome AG it doesn't already own for GBP61 million in cash. Cellzome, a privately owned company with laboratories in Cambridge, U.K., and Heidelberg, Germany, will become part of GSK's R&D organization. Cellzome's proteomics technologies can be used throughout drug discovery from screening to selectivity profiling of compounds in different cells and also in patient samples.